Evidence map›Paper›PMID 29138590›Full record

ArticleJournal of pain research2017

The prevalence of probable neuropathic pain in the US: results from a multimodal general-population health survey.

Marco D DiBonaventura, Alesia Sadosky, Kristen Concialdi, Markay Hopps, Ian Kudel, Bruce Parsons, Joseph C Cappelleri, Patrick Hlavacek, Andrea H Alexander, Brett R Stacey and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of pain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06030297 (Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.), which is not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06030297 nacompletednot on this mapstarted 2023, after this paper: background citation

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

TypeinterventionalSponsorUniversity of UtahRan2023 to 2026Enrolled75ConditionsPeripheral NeuropathyArmsDiode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. UltramicronizedCurrent neuropharmacology · 2024
    Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Marco D DiBonaventuraHealth Outcomes Practice, Kantar Health.
Alesia SadoskyPfizer Inc, New York, NY.
Kristen ConcialdiHealth Outcomes Practice, Kantar Health.
Markay HoppsPfizer Inc, New York, NY.
Ian KudelHealth Outcomes Practice, Kantar Health.
Bruce ParsonsPfizer Inc, New York, NY.
Joseph C CappelleriPfizer Inc, Groton, CT.
Patrick HlavacekPfizer Inc, New York, NY.
Andrea H AlexanderPfizer Inc, New York, NY.
Brett R StaceyUniversity of Washington, Seattle, WA.
John D MarkmanUniversity of Rochester School of Medicine and Dentistry, Rochester, NY.
John T FarrarUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, US.
Pfizer (United States) · USKantar Health (United States) · USUniversity of Pennsylvania · USUniversity of Rochester · USUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prevalence of neuropathic pain (NeP) has been estimated within specific health conditions; however, there are no published data on its broad prevalence in the US. The current exploratory study addresses this gap using the validated PainDetect questionnaire as a screener for probable NeP in a general-population health survey conducted with a multimodal recruitment strategy to maximize demographic representativeness. MATERIALS AND

methodsAdult respondents were recruited from a combination of Internet panels, telephone lists, address lists, mall-based interviews, and store-receipt invitations using a random stratified-sampling framework, with strata defined by age, sex, and race/ethnicity. Older persons and minorities were oversampled to improve prevalence estimates. Results were weighted to match the total adult US population using US Census data. Demographic information was collected, and respondents who experienced physical pain in the past 12 months completed the PainDetect and provided additional pain history. A cutoff score of 19 or greater on the PainDetect was used to define probable NeP.

resultsA total of 24,925 respondents (average response rate 2.5%) provided demographic data (52.2% female, mean age 51.5 years); 15,751 respondents reported pain (63.7%), of which 2,548 (15.7%, 95% confidence interval 14.9%-16.5%) had probable NeP based on the PainDetect, which was 10% (95% confidence interval 9.5%-10.5%) of all respondents. Among those reporting pain, the prevalence of probable NeP among Blacks and Hispanics was consistently higher than Whites in each age- and sex group. The highest prevalence among those with pain was among male Hispanics 35-44 years (32.4%) and 45-54 years (24.2%) old. The most commonly used medications reported by those with probable NeP were nonsteroidal anti-inflammatory drugs (44.2%), followed by weak opioids (31.7%), antiepileptics (10.9%), and strong opioids (10.9%).

conclusionThis is the first study to provide an estimate of the prevalence of probable NeP in the US, showing significant variation by age and ethnicity.

Indexed as

epidemiologyneuropathic painpain typesprevalence

Identifiers

PMID29138590
PMCPMC5677393
OpenAlexW2765106757

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.